Off-topic for aiqbench

This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.

CR Sanhua Double-Herbs: DC7001A Capsule Granted US FDA Clinical Trial Approval

36KrOctober 11, 20261 min read

36Kr reports that CR Sanhua Double-Herbs announced its wholly-owned subsidiary, Beijing Shuanghe Runchuang Technology, received notification from the US FDA approving clinical trials for the DC7001A capsule. The drug is intended for the treatment of systemic lupus erythematosus and has already obtained approval for drug clinical trials from the National Medical Products Administration.

Read the full article at 36Kr

Read at 36Kr ↗Ask about this article